Millendo announces findings from phase 2b trial of livoletide

JHorsfall • Apr 06, 2020

Millendo Therapeutics is to discontinue development of livoletide as a potential treatment for Prader-Willi Syndrome.

Biopharmaceutical company Millendo Therapeutics has announced the results of its phase 2b trials of livoletide as a potential treatment for individuals with Prader-Willi Syndrome.

The study found that livoletide did not significantly improve hyperphagia and food-related behaviours. As a result, Millendo has now taken the decision to discontinue the livoletide programme in relation to PWS.

To find out more about the outcome of the study, please visit the Millendo website here.
by JHorsfall 14 Feb, 2024
Changes to our membership offer - and to the way we share our news!
by JHorsfall 26 Jan, 2024
Details of three PWS community days announced in Ayr, Skegness and Dorset!
by JHorsfall 02 Nov, 2023
T ARGET NOW REACHED - THANK YOU! You can still support our work by making a donation here .
by JHorsfall 14 Jun, 2023
Can you help with this important piece of PWS research?
by JHorsfall 02 Jun, 2023
The taster sessions will be FREE and we encourage parents, grandparents and children to join in!
by JHorsfall 26 May, 2023
PWSA UK and FPWR UK are kicking off a new collaboration by going orange together!
by JHorsfall 19 May, 2023
Our one-day conference for adults with PWS returns for 2023!
by JHorsfall 19 May, 2023
Three new videos for Awareness Month from Pilates instructor Joakim Valsinger!
by JHorsfall 28 Apr, 2023
Help us raise funds and awareness of Prader-Willi syndrome
by JHorsfall 03 Apr, 2023
Easter can be a particularly challenging time for families in our PWS community. However, there are ways to celebrate without the need to focus on chocolate.
Show More

Share an article

Share by: